Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
申请人:Enanta Pharmaceuticals, Inc.
公开号:US10968249B2
公开(公告)日:2021-04-06
The present invention provides compounds of Formula I,
pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
本发明提供了式 I 的化合物、
包含这些化合物的药物组合物,以及使用这些化合物预防或治疗 FXR 介导或 TGR5 介导的疾病或病症的方法。
Barnett; Morris, Biochemical Journal, 1946, vol. 40, p. 450,451
作者:Barnett、Morris
DOI:——
日期:——
A kinetic and x-ray diffraction study of the solid state rearrangement of methyl p-dimethylaminobenzenesulfonate. Reaction rate enhancement due to proper orientation in a crystal
作者:Chaim N. Sukenik、Jose A. P. Bonapace、Neil S. Mandel、Pui-Yan Lau、Gordon Wood、Robert G. Bergman
DOI:10.1021/ja00445a030
日期:1977.2
Kuhn; Brydowna, Chemische Berichte, 1937, vol. 70, p. 1333,1339
作者:Kuhn、Brydowna
DOI:——
日期:——
Houben; Schreiber, Chemische Berichte, 1920, vol. 53, p. 2354